Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Spyre Therapeutics ( (SYRE) ) has shared an update.
On January 12, 2026, Spyre Therapeutics announced that it expects six proof-of-concept readouts in 2026 from its Phase 2 SKYLINE platform trial in ulcerative colitis and SKYWAY basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with SKYLINE Part A data now accelerated to begin in the second quarter and all SKYWAY indications targeted to read out in the fourth quarter. The company reported that enrollment in SKYLINE Part A has been strong, with the SPY001 arm fully enrolled ahead of schedule, and it highlighted a pro forma cash position of $783 million as of September 30, 2025, which it anticipates will fund operations into the second half of 2028, while also strengthening its commercial capabilities through the appointment of former Amgen executive Kate Tansey Chevlen as Chief Commercial Officer, signaling preparation for potential late-stage development and future commercialization in high-revenue autoimmune markets.
The most recent analyst rating on (SYRE) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Spyre Therapeutics stock, see the SYRE Stock Forecast page.
Spark’s Take on SYRE Stock
According to Spark, TipRanks’ AI Analyst, SYRE is a Neutral.
The score is held back primarily by weak financial performance (large losses and substantial ongoing cash burn despite a strong balance sheet). Technicals are moderately supportive with a clear longer-term uptrend and bullish MACD, while valuation remains pressured by negative earnings and no dividend. Corporate events are a positive offset due to encouraging Phase 1 data and strengthened funding.
To see Spark’s full report on SYRE stock, click here.
More about Spyre Therapeutics
Spyre Therapeutics, Inc., based in Waltham, Massachusetts, is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations aimed at redefining the standard of care for inflammatory bowel disease and rheumatic diseases. Its pipeline centers on extended half-life antibodies targeting α4ß7, TL1A, and IL-23, positioning the company in large autoimmune markets with significant unmet medical needs.
Average Trading Volume: 914,848
Technical Sentiment Signal: Hold
Current Market Cap: $2.34B
Find detailed analytics on SYRE stock on TipRanks’ Stock Analysis page.